NCT01033721已完成1 期
A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients With Advanced Neovascular Age-Related Macular Degeneration (AMD)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- Safety-Review AEs, concomitant meds-Vitals, HR, systolic/diastolic BP, temperature, weight-ECG changes; Physical exam-Laboratory parameters-Ophthalmic exam-visual acuity, IOP, slit lamp fundus exam, fundus photography, fluorescein angiography, OCT
研究概览
简要总结
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation. Palomid 529 will be examined to determine if the safety, tolerability and pharmacokinetic profile of single ascending doses when administered intravitreally or subconjunctivally.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Best corrected visual acuity in the study eye between 20/100 and 20/800 (between 53 and 4 ETDRS letters read), and better or equal to 20/200 (minimum of 34 letters read) in the fellow eye.
- •Subfoveal choroidal neovascularization (CNV) due to AMD
- •Total area of the lesion (including blood, neovascularization and scar/atrophy) must be < 12 DA.
- •Only 1 eye will be treated in the study. If both eyes are eligible, the investigator will select the eye with the most active CNV
- •Clear ocular media and adequate pupillary dilatation to permit good stereo fundus photography for screening
- •Intraocular pressure of 21 mm Hg or less
- •Retinal thickness ≥ 250 μm by OCT, with presence of intraretinal or subretinal fluid
排除标准
- •Any retinovascular disease or retinal degeneration other than AMD
- •Serous pigment epithelial detachment without the presence of neovascularization
- •Previous posterior vitrectomy or retinal surgery
- •Any periocular infection in the past 4 weeks
- •Concomitant therapy with anti-VEGF therapies, e.g. Avastin, Lucentis or Macugen, or previous use of these agents within 60 days of screening
- •Concomitant therapy with intravenous or intravitreous corticosteroids or use within 90 days of screening
- •Significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity, or fundus photography
- •Cataract surgery in the study eye within 3 months of screening
- •Intraocular surgery in the study eye within 3 months of screening
- •Presence of ocular infection in the study eye
- •Presence of severe myopia (-8 diopters or greater) in the study eye
结局指标
主要结局
Safety-Review AEs, concomitant meds-Vitals, HR, systolic/diastolic BP, temperature, weight-ECG changes; Physical exam-Laboratory parameters-Ophthalmic exam-visual acuity, IOP, slit lamp fundus exam, fundus photography, fluorescein angiography, OCT
时间窗: 43 days
次要结局
- Efficacy-Mean change in visual acuity by ETDRS testing-Decreased leakage and/or size on FA, decreased retinal thickness in OCT-Decreased fibrosis if detectable based on fundus examination, photography, angiography and OCT(43 days)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast CancerEarly Breast Cancer (Phase 2)Advanced Breast Cancer (Phase 1b)NCT01430585Pfizer14
终止
2 期
Ceritinib Rare Indications Study in ALK+ TumorsTumors With Aberrations in ALKGlioblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic TumorNCT02465528Novartis Pharmaceuticals22
招募中
1 期
Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsMelanoma Stage IVSolid TumorNCT06425926Georgiamune Inc117
终止
1 期
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.Solid TumorsNCT04642365Hoffmann-La Roche49
已完成
2 期
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaDialysis-dependent Chronic Kidney DiseaseAnemiaNCT03799627Akebia Therapeutics175